Balance Sheet
Cash Flow Statement
AmortizationAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Gains from Sales and Divestitures (2020 - 2025)

Historic Gains from Sales and Divestitures for Legend Biotech (LEGN) over the last 5 years, with Q2 2025 value amounting to $250000.0.

  • Legend Biotech's Gains from Sales and Divestitures rose 1240000.0% to $250000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $250000.0, marking a year-over-year increase of 1240000.0%. This contributed to the annual value of $481000.0 for FY2022, which is 5061.6% down from last year.
  • Latest data reveals that Legend Biotech reported Gains from Sales and Divestitures of $250000.0 as of Q2 2025, which was up 1240000.0% from $53000.0 recorded in Q1 2025.
  • Legend Biotech's Gains from Sales and Divestitures' 5-year high stood at $481000.0 during Q4 2022, with a 5-year trough of $2000.0 in Q1 2024.
  • For the 5-year period, Legend Biotech's Gains from Sales and Divestitures averaged around $102307.7, with its median value being $53000.0 (2025).
  • As far as peak fluctuations go, Legend Biotech's Gains from Sales and Divestitures tumbled by 9910.31% in 2024, and later surged by 1240000.0% in 2025.
  • Legend Biotech's Gains from Sales and Divestitures (Quarter) stood at $54000.0 in 2021, then skyrocketed by 790.74% to $481000.0 in 2022, then tumbled by 53.64% to $223000.0 in 2023, then crashed by 99.1% to $2000.0 in 2024, then soared by 12400.0% to $250000.0 in 2025.
  • Its Gains from Sales and Divestitures stands at $250000.0 for Q2 2025, versus $53000.0 for Q1 2025 and $2000.0 for Q3 2024.